Faeth Therapeutics (FTH) Stock Forecast: StockMap's 2-Week Call
FTH stock forecast: StockMap's model calls Faeth Therapeutics Strong Underperform for the two weeks after the Nov 19 close: it expects FTH to trail the growth index. It is a call on the gap, not a price target. Right in 5 of 6 two-week windows on FTH since Aug 24; by chance, a call on the same dates was right 63% of the time.
Faeth Therapeutics last closed at $8.69, -0.34% on the session.
Against the IVW growth benchmark the position is +1.99% over the forecast window.
Faeth Therapeutics' market cap is $224.59M as of November 19, 2026.
Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -54 (behind).
Where FTH sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 0 bullish and 15 bearish.
Agreement across those insights is 100%.
44 daily calls for FTH so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Faeth Therapeutics in the 3rd percentile on return on equity, where 100 is best.
Faeth Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Faeth Therapeutics as the 229th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Faeth Therapeutics ranks 364th of 394 in the group, against a group median of -0.27.